Skip to main content

Pharming announces the successful completion of patient enrolment in the  pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

With completion of enrolment, we move one step closer to making this medicine available for APDS patients around the world.

- Anurag Relan - Chief Medical Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline